1. Introduction

Non-therapeutic gene editing refers to the deliberate modification of an individual's genetic material for purposes other than preventing, diagnosing, or treating a disease. It may involve changing physical characteristics, intelligence-related traits, muscle development, height, appearance, reproductive characteristics, or other inherited biological features.

In Morocco, non-therapeutic gene editing raises important questions concerning constitutional rights, human dignity, medical ethics, public health, reproductive autonomy, genetic privacy, and the protection of future generations.

The central legal distinction is between:

Therapeutic gene editing: Genetic modification intended to prevent or treat a medical condition.

Non-therapeutic gene editing: Genetic modification intended to enhance human characteristics or produce preferred biological traits.

Germline gene editing: Modification of embryos, sperm, or eggs in ways that may transmit genetic changes to future generations.

Somatic gene editing: Modification of cells in an existing individual, without ordinarily transmitting the changes to descendants.

Morocco's legal framework must be examined through its constitutional protections, biomedical research legislation, pharmaceutical regulation, genetic-data protection, and international bioethics commitments.

An important qualification is that Morocco does not have a clearly established, comprehensive statute specifically entitled a prohibition of non-therapeutic human gene editing. Consequently, restrictions must be analysed through applicable legislation and the legal principles governing medical experimentation and human dignity.

2. Constitutional framework governing gene editing

The Moroccan Constitution of 2011 provides the fundamental legal principles relevant to genetic modification.

A. Article 20 – Right to life

Article 20 recognizes the right to life as a fundamental human right protected by law.

This provision is relevant where experimental genetic modification creates serious risks to human life, embryonic development, or the health of future generations.

B. Article 22 – Physical integrity and human dignity

Article 22 prohibits violations of physical and moral integrity and prohibits conduct that undermines human dignity.

Its relevance includes:

Unnecessary genetic modification of human beings.

Experimental genetic enhancement without adequate safeguards.

Genetic interventions involving disproportionate medical risks.

Practices treating human biological characteristics as commercial products.

Genetic experimentation involving persons unable to provide valid consent.

Article 22 provides a constitutional basis for challenging harmful or degrading genetic interventions. However, it does not expressly establish a standalone prohibition of every non-therapeutic gene-editing procedure.

C. Article 24 – Right to privacy

Article 24 protects the privacy of individuals. This protection is important because genetic information can reveal inherited diseases, biological relationships, ancestry, and other highly personal information.

D. Articles 25 and 26 – Scientific freedom and research

These provisions protect freedom of scientific and technical research and recognize the state's responsibility to support scientific development.

However, scientific freedom does not mean that every experiment is legally permissible. Scientific research must operate consistently with human dignity, physical integrity, and applicable statutory safeguards.

Legal significance: Morocco's Constitution requires a balance between scientific progress and protection of human beings.

bdj.mmsp.gov.ma+1

3. Law No. 47-14 of 2019: The principal reproductive-genetics restriction

One of the most important legislative instruments for examining non-therapeutic gene editing in Morocco is Law No. 47-14 on Medically Assisted Reproduction (2019).

This law is particularly relevant to embryo manipulation, genetic selection, reproductive technologies, and interventions affecting the integrity of the human species.

A. Article 3 – Human dignity and integrity

Article 3 requires medically assisted reproduction to respect:

Human dignity.

Human life.

Physical and psychological integrity.

Personal privacy.

Confidentiality of personal information.

This establishes an ethical and legal framework for reproductive genetic technologies.

B. Article 4 – Prohibition of eugenics

Article 4 is particularly significant. It provides that medically assisted reproduction must not undermine the integrity of the human species.

It expressly prohibits:

Reproductive cloning.

Eugenics.

The prohibition of eugenics is particularly relevant to non-therapeutic genetic enhancement.

For example, reproductive genetic interventions intended to create children with preferred physical characteristics, inherited biological advantages, or selected genetic traits may raise serious concerns under this provision.

Nevertheless, the precise legal classification of every embryo-selection or gene-editing technique requires interpretation of the statute and its implementing provisions. The prohibition should not automatically be equated with an express statutory ban on every form of somatic gene editing.

C. Article 5 – Protection of reproductive functions

Article 5 prohibits commercial exploitation of human reproductive functions and prohibits the donation or sale of gametes, embryos, and germinal tissues, as well as surrogacy.

This provision is relevant to commercial reproductive genetic enhancement and the development of markets involving human reproductive material.

D. Article 6 – Prohibition of commercial or industrial embryo use

Article 6 prohibits creating or using human embryos for commercial or industrial purposes. Human embryos may only be conceived within the framework of medically assisted reproduction regulated by the law.

E. Article 7 – Prohibition of embryo research

Article 7 prohibits research on human embryos and fetuses. It also prohibits creating embryos or fetuses for research or experimentation or for purposes outside the legally regulated framework of medically assisted reproduction.

This provision is especially important for non-therapeutic germline gene editing.

For example, an experimental programme that creates human embryos specifically to test genetic modifications for height, intelligence-related characteristics, or other enhancement objectives would encounter a direct statutory prohibition.

Legal conclusion: Law No. 47-14 provides the clearest statutory restrictions against reproductive eugenics and experimental manipulation of human embryos.

Ma Loi+2

4. Law No. 28-13 of 2015: Regulation of biomedical research

The second major legislative instrument is Law No. 28-13 concerning the protection of persons participating in biomedical research.

This legislation establishes requirements for scientific research involving human participants.

A. Article 3 – Fundamental ethical principles

Article 3 establishes that biomedical research must respect:

Human life and health.

Physical and psychological integrity.

Human dignity and privacy.

Voluntary participation.

Informed and express consent.

The non-commercial nature of the human body.

Good clinical research practices.

These requirements are relevant to gene-editing research involving human participants.

B. Articles 4 and 5 – Informed consent

These provisions establish the requirement for free, informed, and express consent.

Participants must receive relevant information about the proposed research and retain the right to refuse participation or withdraw consent.

Consent does not, however, make an otherwise prohibited experiment lawful.

C. Article 12 – Research involving minors

Article 12 restricts biomedical research involving minors and legally protected adults.

Research without direct therapeutic benefit may only be permitted under specific conditions, including:

No foreseeable serious risk to the participant's health.

Potential usefulness to persons with similar characteristics.

The impossibility of conducting the research by another method.

This is particularly important when genetic research involves children who cannot independently make all medical decisions.

D. Article 24 – Authorized research establishments

Article 24 restricts certain biomedical research involving gene therapy and cellular therapies to specified public health establishments and university hospital research sites.

It also requires appropriate technical, material, and human resources and administrative approval of research sites.

E. Article 26 – Government authorization

Interventional biomedical research cannot be conducted without authorization from the competent government authority.

F. Article 27 – Conditions for approval

Article 27 requires:

A favourable opinion from the competent regional ethics committee.

Adequate scientific evidence, including preclinical evidence.

Proportionate risk in relation to expected benefit or research interest.

A legitimate scientific objective.

Appropriate supervision and technical safeguards.

A gene-editing experiment intended exclusively to enhance non-medical characteristics would face particular difficulties satisfying the statutory requirements concerning risk, benefit, and scientific purpose.

Importantly, Article 27 does not itself establish a categorical prohibition of all non-therapeutic research. Its requirements must be applied to the actual purpose and design of the proposed experiment.

Ma Loi+3

5. Law No. 09-08 of 2009: Genetic privacy and data protection

Non-therapeutic gene editing frequently involves the collection, analysis, storage, and transfer of genetic information.

Morocco regulates this area through Law No. 09-08 concerning the protection of individuals in relation to personal-data processing.

Article 1 recognizes genetic information as sensitive personal data.

The law is relevant to:

Genetic sequencing.

DNA databases.

Genetic enhancement research.

Embryonic genetic information.

Genetic profiling and discrimination.

International transfer of genetic information.

The National Commission for the Control of Personal Data Protection (CNDP) supervises compliance with the applicable data-protection framework.

Genetic-data processing generally requires prior authorization where it falls within the sensitive-data categories, subject to applicable statutory exceptions.

The CNDP's announcement of 11 May 2026 concerning genomic information is also significant. It reported that an expert group had developed 17 recommendations following work conducted during 2023–2025. These recommendations demonstrate increasing regulatory attention to genomic information, but should not be confused with a new binding prohibition on gene editing.

cndp.ma+3

6. Specific restrictions on non-therapeutic genetic enhancement

Morocco's legal framework can be applied to different forms of genetic enhancement as follows.

An important distinction concerns preimplantation genetic diagnosis (PGD).

Under Law No. 47-14, Article 1, medically assisted reproduction may be used to prevent transmission of a serious disease. Article 19 regulates preimplantation genetic diagnosis within this medical framework.

Therefore, genetic testing to avoid a serious inherited disease must not automatically be treated as equivalent to selecting embryos for cosmetic or enhancement purposes.

7. Legal liability and penalties

Moroccan legislation establishes significant consequences for violations of reproductive and biomedical research restrictions.

A. Law No. 47-14 – Reproductive genetic offences

Article 40 provides severe criminal penalties for specified prohibited reproductive practices, including reproductive cloning, eugenics, and prohibited embryo research.

The reported statutory penalty is imprisonment for 10–20 years and a fine of MAD 500,000–1,000,000.

Article 41 provides further penalties for specified violations of medically assisted reproduction requirements, including unlawful reproductive procedures.

The precise offence must be matched to the relevant statutory provision; these penalties should not be applied automatically to every form of non-therapeutic somatic gene editing.

Ma Loi+1

B. Law No. 28-13 – Unauthorized biomedical research

Article 62 provides imprisonment of three to five years and a fine of MAD 500,000 for specified unauthorized biomedical research and research conducted contrary to the statutory requirements.

Other provisions address:

Failure to obtain valid informed consent.

Breaches of participant-protection requirements.

Unlawful disclosure of confidential information.

Improper financial inducements to research participants.

Unauthorized international transfer of biological samples.

For example, Article 58 establishes penalties for certain failures to take protective measures, while Article 59 addresses unlawful disclosure of protected information.

Article 34 also establishes the research sponsor's responsibility for compensating participants for research-related harm where the required causal connection is established.

Ma Loi+1

C. Law No. 09-08 – Genetic-data violations

The processing of genetic information without complying with applicable data-protection requirements can result in regulatory and legal consequences.

This is particularly relevant to private genetic-enhancement clinics, commercial DNA-testing companies, research laboratories, and organizations maintaining genetic databases.

8. Important case laws and judicial precedents

A significant qualification is necessary: I have not identified a reported Moroccan judicial judgment directly deciding the legality of non-therapeutic human gene editing, CRISPR enhancement, or heritable genetic modification.

Accordingly, the following decisions are comparative authorities. They are not binding Moroccan precedents, but provide useful legal reasoning for understanding reproductive autonomy, embryo research, genetic selection, and human dignity.

Case 1: Costa and Pavan v. Italy (2012)

European Court of Human Rights · Application No. 54270/10 · Judgment of 28 August 2012

This case concerned a married couple who were carriers of cystic fibrosis and wished to use assisted reproduction and preimplantation genetic diagnosis to avoid transmitting the disease to their child.

Italian legislation restricted access to embryo screening.

The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights, concerning respect for private and family life.

Legal principles:

Reproductive decisions can fall within the protection of private and family life.

Genetic testing for the prevention of a serious inherited disease raises legitimate reproductive-autonomy interests.

Restrictions on reproductive technologies should be consistent and proportionate.

Relevance to Morocco: The decision helps distinguish therapeutic genetic selection from non-therapeutic eugenic enhancement. It also demonstrates why legislation should clearly distinguish disease prevention from enhancement.

HUDOC+1

Case 2: Parrillo v. Italy (2015)

European Court of Human Rights (Grand Chamber) · Application No. 46470/11 · Judgment of 27 August 2015

The applicant wished to donate embryos created through assisted reproduction to scientific research. Italian legislation prohibited such donation.

The Court examined the relationship between embryo research, private life, property interests, and scientific freedom.

It held that the prohibition did not violate Article 8 in the circumstances of the case. It also concluded that the embryos did not constitute possessions protected by Article 1 of Protocol No. 1.

Legal principles:

Embryo research involves complex ethical considerations.

States have discretion when regulating morally sensitive reproductive technologies.

Scientific freedom does not automatically override restrictions intended to protect embryos and human dignity.

Relevance to Morocco: This judgment provides useful comparative reasoning for the restrictions imposed by Article 7 of Moroccan Law No. 47-14, which prohibits research on human embryos and fetuses.

HUDOC

Case 3: Evans v. United Kingdom (2007)

European Court of Human Rights (Grand Chamber) · Application No. 6339/05 · Judgment of 10 April 2007

This case concerned frozen embryos created through assisted reproduction and a disagreement between former partners over whether the embryos could be used.

The Court examined reproductive autonomy, the right to respect for private life, and the interests of individuals involved in embryo creation.

Legal principles:

Reproductive autonomy is an important aspect of private life.

The interests of individuals involved in embryo creation must be balanced.

Legal certainty is important in regulating reproductive technologies.

Relevance to Morocco: The case provides comparative guidance for considering consent, embryo preservation, and reproductive decision-making under Law No. 47-14.

It does not establish a direct legal rule about gene editing or genetic enhancement.

9. International bioethical principles

Morocco's national legislation should also be understood in the context of international bioethics.

A. UNESCO Universal Declaration on the Human Genome and Human Rights (1997)

The Declaration establishes important principles concerning human dignity, genetic equality, and the protection of the human genome.

Article 1 describes the human genome as the heritage of humanity in a symbolic sense.

Article 11 states that practices contrary to human dignity, such as reproductive cloning of human beings, should not be permitted.

B. UNESCO International Declaration on Human Genetic Data (2003)

This Declaration emphasizes:

Protection of genetic information.

Confidentiality.

Informed consent.

Prevention of genetic discrimination.

Responsible use of human genetic information.

C. International bioethics standards

International scientific and medical ethics increasingly emphasize caution concerning heritable human genome editing, particularly where safety, long-term consequences, and the rights of future generations remain uncertain.

These instruments provide ethical and interpretative guidance. They should not automatically be treated as directly enforceable Moroccan criminal prohibitions.

Morocco's applicable treaty obligations must be distinguished from non-binding declarations and recommendations.

IRC+1

10. Regulatory challenges in Morocco

Despite the existence of significant legal protections, several challenges remain.

1. Absence of a dedicated gene-editing statute

Morocco does not have a comprehensive gene-editing law expressly classifying all therapeutic and non-therapeutic genetic interventions.

2. Germline versus somatic editing

The distinction between editing reproductive cells and editing ordinary body cells needs clearer statutory treatment.

3. Cross-border genetic enhancement

Individuals may seek gene-editing services in countries with different regulatory standards. This creates questions concerning jurisdiction, medical liability, and recognition of foreign procedures.

4. Commercialization of genetic enhancement

Private biotechnology companies may market genetic enhancement services without adequate evidence of safety or effectiveness.

5. Protection of future generations

Germline modification may create inherited consequences for individuals who cannot consent to the intervention.

6. Regulatory coordination

Effective enforcement requires coordination among the Ministry of Health, biomedical research ethics committees, pharmaceutical regulators, and the CNDP.

11. Recommendations for strengthening Moroccan legislation

Morocco could improve its regulatory framework through the following measures:

Introduce a dedicated statutory definition of therapeutic and non-therapeutic gene editing.

Expressly regulate human germline genome editing.

Clarify the relationship between the prohibition of eugenics and permissible disease-prevention technologies.

Establish clear licensing requirements for gene-editing laboratories.

Prohibit non-medical enhancement procedures involving serious or disproportionate risks.

Strengthen informed-consent requirements for genetic experimentation.

Establish long-term monitoring obligations for authorized gene therapies.

Improve genetic-data confidentiality and cross-border data-transfer controls.

Establish clear civil and criminal liability for unauthorized genetic interventions.

Develop specialized judicial and regulatory expertise in biotechnology disputes.

12. Conclusion

Morocco has established an important legal foundation for controlling non-therapeutic gene editing through constitutional protections and specific legislation.

Three laws are particularly significant:

Law No. 47-14 of 2019: Prohibits reproductive cloning and eugenics and restricts human embryo research.

Law No. 28-13 of 2015: Regulates biomedical research, informed consent, research authorization, and participant protection.

Law No. 09-08 of 2009: Protects personal information, including sensitive genetic information.

The most important distinction is that Morocco's restrictions on reproductive eugenics and embryo experimentation are considerably clearer than its regulation of non-therapeutic somatic gene editing.

Consequently, it would be legally inaccurate to claim that every form of human genetic enhancement is expressly prohibited by one comprehensive Moroccan statute.

The overall regulatory objective should be to prevent harmful genetic experimentation, protect human dignity, preserve reproductive autonomy, prevent genetic discrimination, and ensure that scientific progress remains consistent with fundamental human rights.

13. Principal legal references

Useful primary legal sources:

Moroccan Law No. 47-14 – Medically Assisted Reproduction.

Moroccan Law No. 28-13 – Biomedical Research.

Moroccan CNDP – Data Protection Legislation.

Constitution of Morocco, 2011.

Costa and Pavan v. Italy.

Parrillo v. Italy.

Academic note: This analysis distinguishes binding Moroccan legislation, comparative judicial decisions, and international ethical declarations. The absence of a directly reported Moroccan gene-editing judgment should be expressly acknowledged in academic or legal research.